SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 424B5
Document Type: 424B5
Date Filed: 2025-12-09
Accession Number: 0001213900-25-119671
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025119671/ea0268926-424b5_synergy.htm

Chunk 6 of 23
Word Count: 1297
Character Count: 8114

Document Content:

net proceeds from this offering for other purposes, and we will have broad discretion in the application of net proceeds from this offering. Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities. DILUTION If you invest in our common stock, your interest will be diluted immediately to the extent of the difference between the public offering price per share and the adjusted net tangible book value per share of our common stock after this offering. Our net tangible book value on September 30, 2025 was approximately $(8.4 million), or $(0.75) per share. “Net tangible book value” is total assets minus the sum of liabilities and intangible assets. “Net tangible book value per share” is net tangible book value divided by the total number of shares outstanding.

After
giving effect to the sale of shares of our common stock in the aggregate amount of $5.5 million in this offering at an assumed offering
price of $1.82 per share, which was the last reported sale price of our common stock on The Nasdaq Capital Market on December 8, 2025,
and after deducting estimated offering commissions and expenses payable by us, our net tangible book value as of September 30, 2025 would
have been approximately $(3.0) million, or $(0.21) per share of common stock. This represents an immediate increase in net tangible book
value of $0.54 per share to our existing stockholders and an immediate dilution in net tangible book value of $2.03 per share to investors
participating in this offering. The following table illustrates this dilution per share to investors participating in this offering:

Assumed offering price per share $	1.82

Net tangible book value per share as of September 30, 2025 $	(0.75	)

Increase per share attributable to new investors $	0.54

Net tangible book value per share after giving effect to this offering $	(0.21	)

Dilution per share to new investors $	2.03

The
table above assumes, for illustrative purposes, that an aggregate of 3,126,373 shares of our common stock are sold at a price of $1.82
per share, the last reported sale price of our common stock on The Nasdaq Capital Market on December 8, 2025, for aggregate net proceeds
of $5.5 million. The shares sold in this offering, if any, will be sold from time to time at various prices.

The above discussion and table
are based on 11,251,853 shares of our common stock outstanding as of September 30, 2025 and excludes, as of that date:

●	excludes 1,452,102 shares of common stock issuable upon
the exercise of outstanding options at a weighted average exercise price of $3.03 per share;

●	excludes 1,052,102 shares of common stock reserved for
future issuance pursuant to the Synergy CHC Corp. 2024 Equity Incentive Plan (the “2024 Equity Incentive Plan”); and

●	excludes 156,000 shares of common stock issuable upon the
exercise of outstanding warrants at a weighted average exercise price of $8.69 per share.

To the extent that any of
our outstanding options or warrants are exercised, we grant additional options or other awards under our stock incentive plan or issue
additional warrants, or we issue additional shares of common stock in the future, there may be further dilution.

DESCRIPTION OF THE COMMON STOCK

As of December 8, 2025, there
were 11,431,926 shares of common stock issued and 11,251,853 shares of common stock outstanding, held of record by approximately 68 stockholders.
Subject to preferential rights with respect to any outstanding preferred stock, all outstanding shares of common stock are of the same
class and have equal rights and attributes.

Dividend Rights

The holders of outstanding
shares of our common stock are entitled to receive dividends out of funds legally available at the times and in the amounts that our Board
of Directors may determine.

Voting Rights

Each holder of our common stock
is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Cumulative voting for
the election of directors is not provided for in our articles of incorporation, which means that the holders of a majority of our shares
of common stock voted can elect all of the directors then standing for election.

Preemptive or Similar Rights

Our common stock is not entitled
to preemptive rights and is not subject to conversion or redemption.

Liquidation Rights

Upon our liquidation, dissolution,
or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our
common stock outstanding at that time after payment of other claims of creditors.

Anti-Takeover Effects of Certain Provisions
of Nevada Law

Effect of Nevada Anti-takeover Statute.
We are subject to Section 78.438 of the Nevada Revised Statutes, an anti-takeover law. In general, Section 78.438 prohibits
a Nevada corporation from engaging in any business combination with any interested stockholder for a period of two years following
the date that the stockholder became an interested stockholder, unless prior to that date, the board of directors of the corporation approved
either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder, or if after the
date that the stockholder becomes an interested stockholder the business combination is approved by the board of directors and by 60%
of the voting power of all disinterested stockholders at either an annual or special meeting of the stockholders of the corporation. Section 78.439
provides that business combinations after the two-year period following the date that the stockholder becomes an interested stockholder
may also be prohibited unless either approved by the corporation’s directors before the stock acquisition, or by a majority of the
disinterested stockholders or unless the price and terms of the transaction meet other criteria set forth in the statute.

Section 78.416 defines “business
combination” to include the following:

●	any merger or consolidation involving the corporation and the
interested stockholder or any other corporation which is an affiliate or associate of the interested stockholder;

●	any sale, transfer, pledge or other disposition of the assets
of the corporation involving the interested stockholder or any affiliate or associate of the interested stockholder if the assets transferred
have a market value equal to 5% or more of all of the assets of the corporation or 5% or more of the value of the outstanding shares
of the corporation or represent 10% or more of the earning power of the corporation;

●	subject to certain exceptions, any transaction that results
in the issuance or transfer by the corporation of any stock of the corporation to an interested stockholder, with a market value of 5%
or more of the value of the outstanding shares of the corporation;

●	the adoption of a plan of liquidation proposed by or under any
arrangement with the interested stockholder or any affiliate or associate of the interested stockholder;

●	any transaction involving the corporation that has the effect
of increasing the proportionate share of the stock of any class or series of voting shares of securities convertible into voting shares
of the corporation beneficially owned by the interested stockholder or any affiliate or associate of the interested stockholder; or

●	the receipt by the interested stockholder or any affiliate or
associate of the interested stockholder of the benefit, except proportionately as a stockholder of the corporation, of any loans, advances,
guarantees, pledges or other financial benefits provided by or through the corporation.

In general, Section 78.423
defines an interested stockholder as any entity or person beneficially owning, directly or indirectly, 10% or more of the outstanding
voting stock of the corporation and any entity or person affiliated with or controlling or controlled by any of these entities or persons.